The International Journal of Medical Science and Health Research
September 29, 2026
Arby Shafara Sekundaputra
Introduction: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and accounts for disproportionate disability and mortality. Electroconvulsive therapy (ECT) has long been the definitive intervention, whereas subanaesthetic intravenous ketamine has emerged as a rapid-acting alternative. Direct head-to-head evidence has accumulated...
International Journal of Innovative Technologies in Social Science
September 28, 2026
Klaudia Karolina Wójcik, Michal Kieres, Krzysztof Sebastian Habirek et al.
The article aims to compare receptor mechanisms related to neurotransmitters for some of the most widely used psychoactive substances - amphetamine, cocaine, ecstasy (MDMA), and psilocybin - and to link these mechanisms to cardiovascular effects, thermoregulation, and neurotoxicity. The review is based mainly on in vitro studies on transporters and receptors, animal models, and controlled...
CNS Spectrums
September 28, 2026
Magda Malewska-Kasprzak, Filip Rybakowski, Monika Dmitrzak-Weglarz
Intravenous ketamine is a rapid-acting intervention for treatment-resistant depression (TRD) in adults with major depressive disorder and bipolar disorder (BD). While efficacy is established, a comprehensive integration of clinical, neurophysiological, biomarker, metabolic, and cognitive predictors remains lacking, limiting precision CNS-targeted therapy. To synthesize recent evidence on...
medRxiv
September 28, 2026
Celia J. A. Morgan, David Nutt
preprint
In the KARE trial, 96 adults with severe alcohol use disorder, abstinent following detoxification, were randomised in a 2×2 factorial design to 3 weekly infusions of ketamine (0.8 mg/kg) or saline, each combined with mindfulness-based psychological support (PS) or alcohol psychoeducation (PE). We re-expressed the trial data on endpoints acceptable to regulators and compared the most and least...
Progress in neuro-psychopharmacology & biological psychiatry
September 26, 2026
Kuan-I Liu, Wei-Chen Lin, Cheng-Ta Li et al.
We examined symptom-level treatment effects and exploratory symptom networks after ketamine in treatment-resistant depression. This post hoc analysis pooled 132 participants assigned to ketamine 0.5 mg/kg or protocol-specific control (66 each) from saline-controlled 2017 and midazolam-controlled 2023 trials. Baseline- and trial-adjusted models assessed Montgomery-Åsberg Depression Rating Scale...
Journal of Psychopharmacology
September 25, 2026
Jennifer Jones, Joseph Redding, Emily Amador
Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches. Ketamine, a rapid-acting glutamate receptor antagonist with neuroplasticity-enhancing properties, has shown promise in the...
Translational Psychiatry
September 24, 2026
Elisa Briem, Peter Stöhrmann, Gregor Dörl et al.
Abstract Ketamine induces a sequence of temporally distinct effects on brain function, yet its impact on reward processing beyond the acute post-administration phase remains unclear. In this single-blind, placebo-controlled, crossover study, 28 healthy participants received 0.5 mg/kg racemic ketamine or placebo via a 40 min intravenous infusion. Functional magnetic resonance imaging was...
Journal of Education, Health and Sport
September 24, 2026
Anna Kamosińska, Julia Pająk, Olga Sławatyniec et al.
Treatment-resistant depression (TRD) in adolescents remains a major clinical challenge because of the limited efficacy of conventional antidepressants and the high risk of suicidal behavior. Ketamine has emerged as a rapidly acting antidepressant with a unique glutamatergic mechanism, promoting neuroplasticity and reducing neuroinflammation. Clinical studies demonstrate significant symptom...
Journal of Affective Disorders
September 23, 2026
Erin Curran, Kristina T. Kumpf, Mina Ansari et al.
Ketamine/esketamine produce rapid antidepressant effects, with growing interest in how acute subjective experiences and the surrounding set and setting shape clinical outcomes. Little is known about how audiovisual adjustments during ketamine/esketamine treatment influence comfort, tolerability, or patient experience, despite their common use in clinical practice. Virtual reality (VR) is one...
Journal of Personalized Medicine
September 23, 2026
Aleksandra Metelska, Wojciech Ziemichód, Hanna Karakuła-juchnowicz
Objectives: A significant problem in the treatment of depressive disorders is the growing number of cases of so-called treatment-resistant depression (TRD). There is evidence of ketamine’s effectiveness in treating TRD, with response rates ranging from 40% to 90%. This review aimed to map available studies on peripheral biomarkers of response to ketamine and esketamine in the treatment of...